Form 4: AngioDynamics Executive to Receive Significant Future Equity Grant Under 10b5-1 Plan

AngioDynamics, Inc. discloses a future equity grant to SVP/GM Chad Campbell, comprising restricted stock units and performance rights, set to vest over several years based on time and performance.

Summary

• Chad Thomas Campbell, SVP/GM, Vascular Access at AngioDynamics, Inc. (ANGO), is scheduled to acquire 26,268 shares of common stock as restricted stock units (RSUs) and 26,268 performance rights on July 16, 2025.
• The acquisition is made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.
• The 26,268 restricted stock units will vest in four equal annual installments, with 25% vesting on July 16, 2026, July 16, 2027, July 16, 2028, and July 16, 2029.
• The 26,268 performance rights represent a contingent right to receive common stock, with the actual number of shares earned ranging from 0% to 200% of the target, based on total shareholder return relative to a peer group over a three-year performance period.
• A potential upward or downward 20% adjustment on the calculated achievement is possible, leading to a total potential payout of up to 240% of the target number of shares.
• Any shares from the performance rights that do not vest at the end of the performance period will be forfeited.
• Following these reported transactions, Chad Campbell will beneficially own 94,076 shares directly.
• A Substitute Power of Attorney was executed on January 20, 2025, appointing Lawrence T. Weiss as a substitute attorney-in-fact for Chad Campbell to handle SEC filings.

Sentiment

Score: 8

Explanation: The grant of significant equity awards, particularly performance-based ones, to a key executive is generally a positive signal, indicating commitment to long-term value creation and aligning management incentives with shareholder interests. The use of a 10b5-1 plan also suggests transparency and pre-planning.

Positives

• The equity grant aligns the executive's long-term interests with those of shareholders through multi-year vesting and performance-based incentives.
• The inclusion of performance rights tied to total shareholder return relative to a peer group directly incentivizes competitive company performance.
• The transaction is made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned and transparent approach to insider transactions.

Negatives

• The actual value realized from the grant is contingent on future stock price performance and, for performance rights, on relative total shareholder return, meaning the final value could be lower than the target.
• There is no immediate cash benefit to the executive from this equity grant.
• Unvested restricted stock units and unearned performance rights are subject to forfeiture if vesting conditions or performance targets are not met.

Risks

• Performance Risk: The number of shares earned from performance rights can vary significantly (0% to 240% of target) based on AngioDynamics' total shareholder return relative to its peer group.
• Forfeiture Risk: Unvested restricted stock units and unearned performance rights will be forfeited if the executive's employment ceases or if performance conditions are not satisfied.
• Market Risk: The ultimate value of the vested shares will fluctuate with the market price of AngioDynamics' common stock.

Future Outlook

The document outlines a future equity compensation plan for a key executive, tying a significant portion of their long-term incentives to the company's stock performance and total shareholder return relative to peers over a multi-year period extending through 2029.

Industry Context

This equity grant is a standard practice for executive compensation in publicly traded companies, particularly within the medical technology sector, aiming to align management incentives with long-term shareholder interests. The use of performance rights based on relative total shareholder return is a common and effective approach to incentivize competitive performance within the industry.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) with a multi-year vesting schedule is a common form of long-term incentive compensation across various industries, including medical technology.
• The inclusion of performance rights tied to Total Shareholder Return (TSR) relative to a peer group is considered a best practice in executive compensation, often observed in leading medical device companies such as Medtronic, Boston Scientific, or Edwards Lifesciences, as it directly links executive pay to competitive market performance.
• The four-year vesting schedule for RSUs, with equal annual installments, is typical for such grants, providing sustained retention and incentive over a significant period.
• The potential payout range for performance rights (0% to 240% of target) is within the normal range for such awards, reflecting a balanced approach to risk and reward based on performance achievement.

Management Changes

Corporate Governance

Related Party Transactions

• The equity grant to Chad Thomas Campbell, a Senior Vice President and General Manager, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the executive's financial interests with long-term shareholder value creation, potentially leading to improved company performance. Minor share dilution from future vesting is a standard consideration for equity compensation.
• Employees: May view this as a positive signal of executive commitment and a standard practice for long-term incentive compensation within the company.

Next Steps

• Vesting of 25% of restricted stock units on July 16, 2026.
• Vesting of 25% of restricted stock units on July 16, 2027.
• Vesting of 25% of restricted stock units on July 16, 2028.
• Vesting of 25% of restricted stock units on July 16, 2029.
• Determination of performance rights payout based on the three-year performance period relative to a peer group.

Key Dates

Recommendation

Keywords

AngioDynamics, ANGO, SEC Form 4, equity grant, restricted stock units, RSUs, performance rights, executive compensation, Rule 10b5-1, Chad Campbell, insider ownership